Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from CASI Pharmaceuticals ( (CASI) ) is now available.
CASI Pharmaceuticals announced that it received a delisting determination from Nasdaq due to its market value of listed securities falling below the minimum requirement for an extended period. The company has appealed the decision and is working on a compliance plan to maintain its Nasdaq listing, which is crucial for its operations and investor confidence.
The most recent analyst rating on (CASI) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Underperform.
CASI Pharmaceuticals receives a low overall stock score due to significant financial challenges, including declining revenue and high leverage. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. These factors collectively contribute to the low score.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. The company is actively involved in clinical studies and holds exclusive global rights to CID-103, with plans for further trials in the U.S. and ongoing studies in immune thrombocytopenia.
Average Trading Volume: 237,807
Technical Sentiment Signal: Strong Sell
Current Market Cap: $21.38M
Learn more about CASI stock on TipRanks’ Stock Analysis page.